AIRS Market Analysis

Wall Street coverage

third-party context

Wall Street coverage

$4.50median target· current $2.30 (+95.7%)3 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratio
EPS (TTM)$-0.16200.0% YoY
Profit margin-7.8%HEALTHCARE
Market cap$153.6MMicro cap

Valuation

Forward P/E
PEG ratio
P/B
1.64
P/S (TTM)
1.02
EV/EBITDA
267.32

Profitability & growth

ROE (TTM)
-12.0%
Operating margin
-0.1%
Revenue growth YoY
-2.5%
Dividend yield
Beta
2.29
Last earnings
Aug 10, 2026 · Estimate $0.02 · Reported $-0.02
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About Airsculpt Technologies Inc

Company profile

Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its…

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
2023 WEST PLATT STREET, TAMPA, FL
Fiscal year end
December
Latest quarter
Jun 30, 2026
Market cap$153.6M
Shares outstanding$72.1M
52W high$12.00
52W low$1.51

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer